A highly selective β1-adrenergic blocker with partial β2-agonist activity derived from ferulic acid, an active component of Ligusticum wallichii Franch

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 5, 1998, Pages 750-757

  Wu, Bin Nan ^a   Huang, Yeun Chih ^a   Wu, Hsien Ming ^a   Hong, Show Jen ^a   Chiang, Lien Chai ^a   Chen, Ing Jun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

1 Adrenoceptor antagonist; Bradycardia response; Ferulic acid; Inotropic and chronotropic effects; Partial 2 agonist activity; Radioligand binding assay

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FERULIC ACID; ISOPRENALINE; METOPROLOL; PARTIAL AGONIST; PROPRANOLOL; ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; COUMARIC ACID; FERULINOLOL; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BETA ADRENERGIC STIMULATION; CHRONOTROPISM; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SELECTIVITY; GUINEA PIG; HEART ATRIUM MUSCLE; HEART MUSCLE CONTRACTILITY; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTILITY; VASCULAR SMOOTH MUSCLE; ANIMAL; BINDING COMPETITION; BLOOD PRESSURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HEART RATE; MEDICINAL PLANT; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BINDING, COMPETITIVE; BLOOD PRESSURE; COUMARIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; MALE; PLANTS, MEDICINAL; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0031596995     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199805000-00014     Document Type: Article

References (28)

1. 1-adrenoceptor antagonist derived from vanillin. Biochem Pharmacol 1994;48:101-9.
2. Wu BN, Yang CR, Yang JM, Chen IJ. A new β-adrenoceptor blocking agent derived from dehydrozingerone. Gen Pharmacol 1994;25:651-9.
3. 1-adrenoceptor antagonist. J Cardiovasc Pharmacol 1996;28:149-57.
4. Wu BN, Ho WC, Chiang LC, Chen IJ. Zingeronolol: a newly developed β-adrenergic blocking agent derived from zingerone, a pungent principle of ginger. Asia Pac J Pharmacol 1996;11:5-12.
5. Sheu MM, Wu BN, Ho WC, et al. Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity. Pharmacology 1997;54:211-24.
6. Chen IJ, Yeh JL, Lo YC, Sheu SH, Lin YT. Capsinolol: the tirst β-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart. Br J Pharmacol 1996;119: 7-14.
7. 2-agonist and calcium mobilization inhibition associated vasorelaxant activities. Drug Dev Res 1997;40:239-50.
8. Ozaki Y. Antiinflammatory effect of tetramethylpyrazine and terulic acid. Chem Pharm Bull 1992;40:954-6.
9. Huang MT, Smart RC, Wong CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988;48:5941-6.
10. Chawla AS, Singh M, Murthy MS, Gupta M, Singh H. Anti-inflammatory action of ferulic acid and its esters in carrageenan induced rat paw oedema model. Indian J Exp Biol 1987;25:187-9.
11. Ozaki Y, Ma JP. Inhibitory effects of tetramethylpyrazine and ferulic acid on spontaneous movement of rat uterus in situ. Chem Pharm Bull 1990;38:1620-3.
12. Graf E. Antioxidant potential of ferulic acid. Free Radic Biol Med 1992;13:435-48.
13. Zaroslinski J, Borgman RJ, O'Donnell JP, et al. Ultra short acting beta blockers: a proposal for the treatment of the critically ill patient. Life Sci 1982;31:899-907.
14. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from the MAPHY Study. Am J Hypertens 1991;4:151-8.
15. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomized trial. Lancet 1981;2:823-7.
16. Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol 1990;66:251-60.
17. 1-adrenoceptor antagonist bisoprolol. Arzneimittelforschung 1986;36:200-8.
18. Prichard BNC, Tomlinson B. The additional properties of beta adrenoceptor blocking drugs. J Cardiovasc Pharmacol 1986;8: 1-15.
19. 3 adrenoceptor agonist. Br J Pharmacol 1994;112:55-8.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
21. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 1959;14:48-57.
22. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-108.
23. Scatchard G. The attraction of protein for small molecules and ions. Ann N Y Acad Sci 1949;51:660-72.
24. Regoli G. Pressor action of beta blocking agents in rats. Can J Physiol Pharmacol 1970;48:481-9.
25. Kaumann AJ, Blinks JR. Stimulant and depressant effects of β-adrenoceptor blocking agents on isolated heart muscle: a positive inotropic effect not mediated through adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1980;311:205-18.
26. Harada S, Ban T, Fujita T, Koshiro A. Negative inotropic effects and the hydrophobicity of beta-adrenergic blocking agents. Arch Int Pharmacodyn 1981;252:262-71.
27. Porzig H, Becker C, Reuter H. Competitive and non-competitive interactions between specific ligands and beta-adrenoceptors in living cardiac cells. Naunyn Schmiedebergs Arch Pharmacol 1982;321:89-99.
28. Pauwels PJ, Gommeren W, Lommen GV, Janssen PAJ, Leysen JE. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various β-adrenergic blockers. Mol Pharmacol 1988;34:843-51.